Targeted mutation analysis of endometrial clear cell carcinoma

Histopathology

Volumn 66, Issue 5, 2015, Pages 664-674

  Hoang, Lien N ^a   Mcconechy, Melissa K ^a   Meng, Bo ^b   Mcintyre, John B ^c   Ewanowich, Carol ^b   Gilks, Cyril Blake ^a   Huntsman, David G ^a   Köbel, Martin ^c   Lee, Cheng Han ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

Author keywords

Clear cell carcinoma; Endometrial cancer; Next generation sequencing; TP53

Indexed keywords

ESTROGEN RECEPTOR; HEPATOCYTE NUCLEAR FACTOR 1BETA; MISMATCH REPAIR PROTEIN; NAPSIN A; PROTEIN; UNCLASSIFIED DRUG; DNA; PHOSPHOPROTEIN PHOSPHATASE 2; PPP2R1A PROTEIN, HUMAN; PROTEIN P53; TP53 PROTEIN, HUMAN; TUMOR PROTEIN;

ADULT; AGED; ARID1A GENE; ARTICLE; CARCINOGENESIS; CLEAR CELL CARCINOMA; CLINICAL ARTICLE; CONTROLLED STUDY; CTNNB1 GENE; ENDOMETRIAL CLEAR CELL CARCINOMA; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CARCINOMA; FEMALE; GENE FUNCTION; GENE MUTATION; GENOME ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; MUTATIONAL ANALYSIS; NEXT GENERATION SEQUENCING; PPP2R1A GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PTEN GENE; TUMOR GENE; TUMOR SUPPRESSOR GENE; ADENOCARCINOMA; ENDOMETRIUM TUMOR; GENETICS; MIDDLE AGED; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; VERY ELDERLY;

ADENOCARCINOMA, CLEAR CELL; AGED; AGED, 80 AND OVER; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; MUTATION; NEOPLASM PROTEINS; PROTEIN PHOSPHATASE 2; REAL-TIME POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84924581700     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12581     Document Type: Article

References (33)

1. Gadducci A, Cosio S, Spirito N, Cionini L. Clear cell carcinoma of the endometrium: a biological and clinical enigma. Anticancer Res. 2010; 30; 1327-1334.
2. Olawaiye AB, Boruta DM II. Management of women with clear cell endometrial cancer: a Society of Gynecologic Oncology (SGO) review. Gynecol. Oncol. 2009; 113; 277-283.
3. Fadare O, Zheng W, Crispens MA et al. Morphologic and other clinicopathologic features of endometrial clear cell carcinoma: a comprehensive analysis of 50 rigorously classified cases. Am. J. Cancer Res. 2013; 3; 70-95.
4. Fadare O, Parkash V, Dupont WD et al. The diagnosis of endometrial carcinomas with clear cells by gynecologic pathologists: an assessment of interobserver variability and associated morphologic features. Am. J. Surg. Pathol. 2012; 36; 1107-1118.
5. Gilks CB, Oliva E, Soslow RA. Poor interobserver reproducibility in the diagnosis of high-grade endometrial carcinoma. Am. J. Surg. Pathol. 2013; 37; 874-881.
6. Han G, Sidhu D, Duggan MA et al. Reproducibility of histological cell type in high-grade endometrial carcinoma. Mod. Pathol. 2013; 26; 1594-1604.
7. DeLair D, Oliva E, Kobel M, Macias A, Gilks CB, Soslow RA. Morphologic spectrum of immunohistochemically characterized clear cell carcinoma of the ovary: a study of 155 cases. Am. J. Surg. Pathol. 2011; 35; 36-44.
8. Hoang LN, Han G, McConechy M et al. Immunohistochemical characterization of prototypical endometrial clear cell carcinoma - diagnostic utility of HNF-1beta and oestrogen receptor. Histopathology 2014; 64; 585-596.
9. Fadare O, Desouki MM, Gwin K et al. Frequent expression of napsin A in clear cell carcinoma of the endometrium: potential diagnostic utility. Am. J. Surg. Pathol. 2014; 38; 189-196.
10. Skirnisdottir I, Bjersand K, Akerud H, Seidal T. Napsin A as a marker of clear cell ovarian carcinoma. BMC Cancer 2013; 13; 524.
11. Yamashita Y, Nagasaka T, Naiki-Ito A et al. Napsin A is a specific marker for ovarian clear cell adenocarcinoma. Mod. Pathol. 2014; doi: 10.1038/modpathol.2014.61. [Epub ahead of print]. PMID: 24721826
12. Fadare O, Gwin K, Desouki MM et al. The clinicopathologic significance of p53 and BAF-250a (ARID1A) expression in clear cell carcinoma of the endometrium. Mod. Pathol. 2013; 26; 1101-1110.
13. Fadare O, Renshaw IL, Liang SX. Does the loss of ARID1A (BAF-250a) expression in endometrial clear cell carcinomas have any clinicopathologic significance? A pilot assessment J. Cancer 2012; 3; 129-136.
14. Kobel M, Kalloger SE, Lee S et al. Biomarker-based ovarian carcinoma typing: a histologic investigation in the ovarian tumour tissue analysis consortium. Cancer Epidemiol. Biomarkers Prev. 2013; 22; 1677-1686.
15. Kuo KT, Mao TL, Jones S et al. Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am. J. Pathol. 2009; 174; 1597-1601.
16. McIntyre JB, Nelson GS, Ghatage P et al. PIK3CA missense mutation is associated with unfavorable outcome in grade 3 endometrioid carcinoma but not in serous endometrial carcinoma. Gynecol. Oncol. 2014; 132; 188-193.
17. Yamamoto S, Tsuda H, Takano M, Iwaya K, Tamai S, Matsubara O. PIK3CA mutation is an early event in the development of endometriosis-associated ovarian clear cell adenocarcinoma. J. Pathol. 2011; 225; 189-194.
18. Hoang LN, McConechy MK, Koebel M et al. Histotype-genotype correlation in 36 high-grade endometrial carcinomas. Am. J. Surg. Pathol. 2013; 37; 1421-1432.
19. Hammond ME, Hayes DF, Wolff AC, Mangu PB, Temin S. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J. Oncol. Pract. 2010; 6; 195-197.
20. Kobel M, Reuss A, Bois A et al. The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas. J. Pathol. 2010; 222; 191-198.
21. Meng B, Hoang LN, McIntyre JB et al. POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium. Gynecol. Oncol. 2014; 134; 15-19.
22. Kandoth C, Schultz N, Cherniack AD et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013; 497; 67-73.
23. Kuhn E, Wu RC, Guan B et al. Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses. J. Natl Cancer Inst. 2012; 104; 1503-1513.
24. Le Gallo M, O'Hara AJ, Rudd ML et al. Exome sequencing of serous endometrial tumours identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes. Nat. Genet. 2012; 44; 1310-1315.
25. McConechy MK, Anglesio MS, Kalloger SE et al. Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas. J. Pathol. 2011; 223; 567-573.
26. McConechy MK, Ding J, Cheang MC et al. Use of mutation profiles to refine the classification of endometrial carcinomas. J. Pathol. 2012; 228; 20-30.
27. Zhao S, Choi M, Overton JD et al. Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma. Proc. Natl Acad. Sci. USA 2013; 110; 2916-2921.
28. Jones S, Wang TL, Le Shih M et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 2010; 330; 228-231.
29. Wiegand KC, Shah SP, Al-Agha OM et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N. Engl. J. Med. 2010; 363; 1532-1543.
30. An HJ, Logani S, Isacson C, Ellenson LH. Molecular characterization of uterine clear cell carcinoma. Mod. Pathol. 2004; 17; 530-537.
31. Garg K, Shih K, Barakat R, Zhou Q, Iasonos A, Soslow RA. Endometrial carcinomas in women aged 40 years and younger: tumours associated with loss of DNA mismatch repair proteins comprise a distinct clinicopathologic subset. Am. J. Surg. Pathol. 2009; 33; 1869-1877.
32. Fadare O, Liang SX. Diagnostic utility of hepatocyte nuclear factor 1-beta immunoreactivity in endometrial carcinomas: lack of specificity for endometrial clear cell carcinoma. Appl. Immunohistochem. Mol. Morphol. 2012; 20; 580-587.
33. Yamamoto S, Tsuda H, Aida S, Shimazaki H, Tamai S, Matsubara O. Immunohistochemical detection of hepatocyte nuclear factor 1beta in ovarian and endometrial clear-cell adenocarcinomas and nonneoplastic endometrium. Hum. Pathol. 2007; 38; 1074-1080.